Physician profile

Vick S Dicarlo

Neonatal-Perinatal Medicine · Birmingham, AL

NPI 1770561276

$733.66

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Neonatal-Perinatal Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$387.57

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $145.65 2020-2024
Sobi, INC $137.50 2019-2023
Mallinckrodt Hospital Products INC. $134.63 2023 Inomax
Mallinckrodt Enterprises LLC $122.85 2019
Chiesi USA, INC. $80.00 2019
Fisher & Paykel Healthcare INC $78.58 2024 Fisher & Paykel Healthcare
Medtronic, INC. $17.53 2023 Sonarmed Airwave
Sanofi Pasteur INC. $16.92 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vick S Dicarlo

$733.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/755624/vick-s-dicarlo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.